- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946965
A Prospective External Control Arm Study in Colorectal Cancer (COLOSSAL)
NPM-009/COLOSSAL: A Prospective, Always-On Study to Generate Standardized External Control Arms Across Metastatic and MRD-Positive Early-Stage Colorectal Cancer
The goal of this observational, external control arm study is to make clinical trials faster, speed up developments of new therapies, and make trials more accessible to patients being treated at community oncology clinics.
Study Overview
Status
Conditions
Detailed Description
The purpose of this research is to better understand what treatments are given to patients with colorectal cancer, how the disease responds to treatments, and the generate reliable data that can be used as a comparison for new drugs in development.
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients with early stage or metastatic colorectal cancer
Description
Global Inclusion Criteria:
- 18 years at the time of initial colorectal cancer diagnosis
- Able to understand and provide informed consent
- Pathologically confirmed colorectal cancer per College of American Pathologists (CAP) guidelines
- Evidence of biomarker testing on tissue and/or blood
Early Stage CRC Inclusion Criteria
- Stage II-III disease per AJCC
- Positive ctDNA MRD results for specimen collected 4-8 weeks after curative intent surgery and before any adjuvant therapy
- Planning to start adjuvant therapy, or started it within the past 6 weeks prior to enrollment
- ECOG performance status of 0 or 1, documented on or within 21 days before the start of adjuvant therapy
- CT of the chest, abdomen, and pelvis (CT CAP) with contrast performed after surgery and up to 6 weeks prior to the start of adjuvant therapy
Metastatic CRC Inclusion Criteria
- Stage IV disease per AJCC or metastatic recurrence
- Planning to start adjuvant therapy, or started within the past 6 weeks prior to enrollment
- ECOG performance status of 0 or 1 documented on or within 21 days before the start of the new line of therapy
- CT of the chest, abdomen, and pelvis (CT-CAP) with contrast performed after surgery and up to 6 weeks prior to the start of a new line of therapy
Exclusion Criteria:
- Current enrollment in an interventional clinical trial
- Active therapy for a second, unrelated malignancy (excluding hormonal adjuvant therapy for breast cancer)
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
|---|
|
Early Stage MRD positive
|
|
Metastatic disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression Free Survival (PFS)
Time Frame: 5 years
|
Time from index date to the first evidence of progression assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 for on protocol imaging, or death, whichever occurs first. bicrPFS (months)=[(earliest date of BICR progression, death, or censoring-index date) +1] / 30.4375 |
5 years
|
|
Overall Response Rate (ORR)
Time Frame: 5 years
|
Proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) during a given line of therapy, from index until progression or the start of the next line, whichever occurs first, assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 for on-protocol imaging. Ranked CR ≥ PR ≥ stable disease (SD) ≥ progressive disease (PD) ≥ not evaluable (NE). CR and PR are confirmed by a subsequent assessment at least 28 days later. When the minimum interval is not met, BOR is determined by subsequent assessments. Participants lost to follow-up after an SD assessment that does not meet the minimum interval have a BOR of NE. bicrORR (%) = (number of participants with BOR of CR or PR from index until earliest date of BICR progression or next line start ÷ number of participants in the response population) × 100 |
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Next Treatment (TTNT)
Time Frame: 5 years
|
Time from index to the start of the next line of therapy or death, whichever occurs first. Participants who do not initiate a next line of therapy are censored at earliest of loss to followup and data cutoff. TTNT (months) = [(earliest date of next line start, death, or censoring - index date) + 1] ÷ 30.4375. |
5 years
|
|
Overall Survival (OS)
Time Frame: 5 years
|
Time from index to death from any cause. A missing date of death indicates the participant is alive at data cutoff, and the participant is censored at data cutoff. OS (months) = [(earliest date of death or censoring - index date) + 1] ÷ 30.4375 |
5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NPM-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.